Overall survival between veterans with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone with kidney disease.

被引：0
|
作者：
Wilson, Robert
Doherty, Jason M.
Luo, Suhong
Candelieri-Surette, Danielle
Eaton Jr, Daniel B.
Schoen, Martin W.
机构：
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] St Louis Univ, Dept Hlth & Clin Outcomes Res, St Louis, MO USA
[3] St Louis VA Med Ctr, St Louis, MO USA
[4] Univ Massachusetts Lowell, Lowell, MA USA
[5] VA St Louis Hlth Care Syst, St Louis, MO USA
[6] St Louis Vet Affairs Med Ctr, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.76
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
    Daniel J. George
    Krishnan Ramaswamy
    Ahong Huang
    David Russell
    Jack Mardekian
    Neil M. Schultz
    Nora Janjan
    Stephen J. Freedland
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 524 - 530
  • [22] Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
    George, Daniel J.
    Ramaswamy, Krishnan
    Huang, Ahong
    Russell, David
    Mardekian, Jack
    Schultz, Neil M.
    Janjan, Nora
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) : 524 - 530
  • [23] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Kawahara, Takashi
    Saigusa, Yusuke
    Yoneyama, Shuko
    Kato, Masashi
    Kojima, Ippei
    Yamada, Hiroshi
    Kamihira, Osamu
    Tabata, Kenichi
    Tsumura, Hideyasu
    Iwamura, Masatsugu
    Makiyama, Kazuhide
    Uemura, Hiroji
    Miyoshi, Yasuhide
    BMC CANCER, 2023, 23 (01)
  • [24] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Takashi Kawahara
    Yusuke Saigusa
    Shuko Yoneyama
    Masashi Kato
    Ippei Kojima
    Hiroshi Yamada
    Osamu Kamihira
    Kenichi Tabata
    Hideyasu Tsumura
    Masatsugu Iwamura
    Kazuhide Makiyama
    Hiroji Uemura
    Yasuhide Miyoshi
    BMC Cancer, 23
  • [25] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [26] Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 804 - 804
  • [27] Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 800 - 801
  • [28] Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer
    Pilon, Dominic
    Queener, Marykay
    Lefebvre, Patrick
    Ellis, Lorie A.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (08) : 777 - 784
  • [29] PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
    Espana, Sofia
    de Olza, Maria Ochoa
    Sala, Nuria
    Piulats, Josep Maria
    Ferrandiz, Ulises
    Etxaniz, Olatz
    Heras, Lucia
    Buisan, Oscar
    Pardo, Juan Carlos
    Suarez, Jose F.
    Barretina, Pilar
    Comet, Josep
    del Muro, Xavier Garcia
    Sumoy, Lauro
    Font, Albert
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10251 - 10260
  • [30] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
12345